Edaravone - Mitsubishi Tanabe Pharma

Drug Profile

Edaravone - Mitsubishi Tanabe Pharma

Alternative Names: 1-phenyl-3-methyl-5-pyrazolone; Edarabone; MCI-186; MT 1186; Norphenazone; Phenylmethylpyrazolone; Radicava; Radicut; Radicut Bag

Latest Information Update: 11 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Mitsubishi Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
  • Class Neuroprotectants; Pyrazolones; Small molecules
  • Mechanism of Action Antioxidants; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Amyotrophic lateral sclerosis; Cerebral infarction
  • Phase II Stroke
  • Discontinued Myocardial ischaemia; Parkinson's disease; Reperfusion injury; Subarachnoid haemorrhage

Most Recent Events

  • 03 Oct 2018 Registered for Amyotrophic lateral sclerosis in Canada (IV)
  • 24 Sep 2018 Mitsubishi Tanabe Pharma Corporation terminates a phase II trial in Stroke in Japan due to business objectives have changed (IV) (NCT03346538)
  • 10 Sep 2018 Mitsubishi Tanabe Pharma Corporation plans a phase I trial in volunteers in Czechia, Hungary and Slovakia (NCT03664544)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top